Background Gastric dysplasia is classified as adenomatous/type I (intestinal phenotype) and foveolar or pyloric/ type II (gastric phenotype) according to morphological (architectural and cytological) features. The immunophenotypic classification of dysplasia, based on the expression of the mucins, CD10 and CDX2, recognizes the following immunophenotypes: intestinal (MUC2, CD10, and CDX2); gastric (MUC5AC and/or MUC6, absence of CD10, and absent or low expression of CDX2); hybrid (gastric and intestinal markers); and null.
Introduction
At present, gastric carcinoma (GC) has significant morbidity/mortality impact, being the fourth most common cancer worldwide and the second most deadly [1] .
According to Laurén's [2] classification, there are two main subtypes of GC, intestinal and diffuse, which differ in epidemiology, pathogenesis, morphology, and molecular features [2, 3] . According to the Correa [4] model, gastric cancer develops along a cascade of lesions encompassing Helicobacter pylori-induced chronic superficial gastritis, chronic atrophic gastritis, intestinal metaplasia, dysplasia, and ultimately invasive adenocarcinoma. Gastric dysplasia is neoplastic in nature and is a direct precursor of GC, as well as a risk factor of carcinoma in other locations of the stomach [5, 6] .
Dysplasia is graded as low-or high grade on the basis of architectural and cell features. Further, according to the histomorphological profile, dysplasia may be classified as adenomatous/type I (intestinal phenotype) and foveolar or pyloric/type II (gastric phenotype). The two types may be distinguished by the immunoexpression of the mucins, CD10 and CDX2 (intestinal/adenomatous: MUC2, CD10, and CDX2; gastric/foveolar: MUC5AC and/or MUC6, absence of CD10, and low or absent expression of CDX2) [7] [8] [9] . Cases with hybrid differentiation may also occur as well as null cases in which there is no expression of the aforementioned markers [8] .
A relationship has been reported between the histological grade and the immunohistochemical profiles of dysplasia: in one study, 81.8 % of low-grade dysplasia expressed intestinal markers, and 72.2 % of high-grade dysplasia showed markers of gastric differentiation with variable expression of intestinal markers [10] . In another study, foveolar and hybrid subtypes were also significantly associated with high-grade dysplasia [8] .
In this study we aimed at analyzing the relationship between different types of gastric dysplasia (based on histotypes and grading) and the immunohistochemical profile according to the expression of markers of cell differentiation (MUC5AC, MUC6, MUC2, CD10). The expression of CDX2, Ki-67, TP53, HER2, and neuroendocrine markers (chromogranin and synaptophysin) was also evaluated.
Materials and methods
A series of 66 cases of epithelial dysplasia of the stomach identified in endoscopic submucosal dissection (ESD) specimens were retrieved retrospectively from the files of the Department of Pathology, Centro Hospitalar São João, between June 2010 and June 2013. The cases encompassed superficial nonpolypoid dysplastic lesions (0-II), including slightly elevated (0-IIa), flat (0-IIb), and slightly depressed (0-IIc) lesions, according to the Paris classification [11] . In 20 cases a coexistent intramucosal carcinoma was identified. The study was approved by the Ethical Committee of the Hospital. The clinicopathological features of the cases are summarized in Table 1 .
Tissues were fixed in neutral buffered 10 % formalin, embedded in paraffin, and cut into 3-lm-thick sections.
The lesions were classified on hematoxylin and eosin (H&E)-stained slides as adenomatous/type I (intestinal phenotype) and foveolar or pyloric/type II (gastric phenotype), according to the WHO classification [3] . The adenomatous/intestinal subtype resembles colonic adenomas, with crowded, tubular glands lined by atypical columnar cells with overlapping, pencillate, hyperchromatic and/or pleomorphic nuclei, with pseudostratification and mucin. The foveolar or pyloric/gastric phenotype is characterized by cuboid/low columnar cells, with round to oval nuclei and clear or eosinophilic cytoplasm.
The grade of the dysplasia was evaluated according to WHO 2010 criteria [3] . Low-grade dysplasia shows minimal architectural disarray and only mild to moderate cytological atypia; the nuclei are elongated/oval, polarized, and basally located and the mitotic activity is mild to moderate. High-grade dysplasia presents pronounced architectural disarray, such as complex branching or fusion of glands; the neoplastic cells are usually cuboidal, rather than columnar, with a high nuclear/cytoplasm ratio, high number of mitoses, occasionally atypical, and nuclei within the luminal zone of the epithelium with loss of polarity. The diagnosis of invasive carcinoma was performed when invasion of the lamina propria or muscularis mucosae occurred.
Immunohistochemical staining was performed with antibodies against MUC2, MUC5AC, MUC6, CD10, CDX2, chromogranin, synaptophysin, Ki-67, HER2, and TP53 (Table 2 ). Samples were processed in the automatic equipment Benchmark ULTRA using the Ultraview Universal DAB kit (Ventana Medical Systems, Roche Group). Each sample was heated and deparaffinized, followed by antigen recovery through heat and high-pH buffer solution.
Each primary antibody was incubated in an individually optimized time and temperature, followed by application of the detection system and contrast with hematoxylin and bluing reagent from the same manufacturer.
Immunoreactivity was scored as follows: the immunoexpression of MUC2, MUC5AC, MUC6, CD10, synaptophysin, and chromogranin was scored as positive when C5 % of the dysplastic cells displayed immunoreactivity. HER2 immunoexpression was scored according to Rüsc-hoff et al. [12] : 0, absence of immunoreactivity; 1?, tumor cell cluster with faint or barely perceptible membrane reactivity irrespective of percentage of immunoreactive cells; 2?, tumor cell cluster with weak to moderate (complete, lateral, or basolateral) reactivity irrespective of the percentage of immunoreactive cells; 3?, tumor cell cluster with strong (complete, lateral, or basolateral) reactivity irrespective of the percentage of immunoreactive cells; for scoring purposes any nuclear or cytoplasmic background staining was disregarded. The immunoexpression of CDX2 was considered positive when C25 % of the dysplastic cells displayed immunoreactivity [9] ; immunoexpression of Ki-67 and TP53 was classified as absent/low when immunoreactivity was displayed in \50 % of the dysplastic cells and high in the presence of C50 % positive cells [13] .
Detection of the number of copies of the HER2 gene was performed in the cases scored as 2? and 3? by immunohistochemistry with the silver-enhanced in situ hybridization (SISH) automated technique using the BenchMark XT equipment and the INFORM HER2 SISH probe (Ventana Medical Systems). The HER2/Chr17 ratio of each case was calculated using a minimum of 40 cells in two independent areas of dysplasia. Cases were assigned a score based on the guideline recommendations for HER2 testing in gastric cancer according to Rüschoff et al. [12] : negative, ratio HER2:Cr17 \ 2.0 with \4 copies of HER2 gene; borderline, ratio HER2:Cr17 \ 2.0 with C4 and \6 copies of HER2 gene; positive, ratio HER2:Cr17 \ 2.0 with C6 copies of HER2 gene or ratio HER2:Cr17 C 2.0.
Statistical analysis
Appropriate statistical methods were used regarding the type of sample and its distribution. The data were analyzed with SPSS software v. 19.0 (SPSS Software, Chicago, IL, USA), using the chi-squared or Fischer's test. A p value \0.05 was considered statistically significant.
Results
The study group was composed of 66 cases (Table 1) , classified by conventional histology on H&E-stained slides as foveolar or pyloric/gastric (n = 24; 36 %) or adenomatous/intestinal (n = 42; 64 %) ( Fig. 1 ) and graded as low grade (n = 37; 56 %) or high grade (n = 29; 44 %). According to the immunophenotype, the cases were classified as gastric type (n = 25; 37.9 %) (Fig. 2a, c, e, g, i) , intestinal type (n = 22; 33.3 %) (Fig. 2b, d , f, h, j), hybrid type (n = 17; 25.8 %), or null (n = 2, 3.0 %). The latter were not considered for subsequent analysis. Table 3 summarizes the expression of the different markers in the three immunophenotypes of gastric dysplasia. Statistically significant differences were observed between the immunophenotypes regarding the expression of MUC2 (p = 0.002), CD10 (p \ 0.0001), MUC5AC (p \ 0.0001), and MUC6 (p \ 0.0001). Cases with low/ absent expression of CDX2 were observed only in the gastric immunophenotype (p = 0.015).
The frequency of cases with high expression of Ki-67 was significantly greater in the gastric and hybrid (84.0 % and 94.1 %, respectively) than in the intestinal (63.6 %) immunophenotypes (p = 0.05).
The frequency of cases with high expression of TP53 was significantly higher in the intestinal and hybrid (40.9 % and 52.9 %, respectively) than in the gastric (16.0 %) immunophenotypes (p = 0.034).
The expression of HER2 (Fig. 3a) was homogeneous and seen in areas of both dysplasia and adenocarcinoma. In dysplasia, scores 2? and 3? were observed in 11 lesions with gastric or hybrid immunophenotypes (28.0 % and 23.5 %, respectively) and not detected in the intestinal immunophenotype (p = 0.029).
HER2 amplification (Fig. 3b) was observed in three cases of dysplasia, immunophenotyped as gastric (n = 1) and hybrid (n = 2), as well as in one adenocarcinoma identified in the neighborhood of a dysplastic lesion.
Regarding the neuroendocrine markers, the frequency of the expression of synaptophysin was significantly higher in intestinal (81.8 %) than in hybrid and gastric (58.8 % and 32.0 %, respectively) immunophenotypes (p = 0.003). Similar observations were made for the expression of chromogranin, displayed predominantly in intestinal (95.2 %) in comparison with hybrid and gastric (70.6 % and 28.0 %, respectively) immunophenotypes (p \ 0.0001). In some cases, immunophenotyped as intestinal, small nests of neuroendocrine cells were observed. Table 4 shows the relationship between the immunophenotypes and the histotypes of gastric dysplasia (adenomatous/intestinal and foveolar or pyloric/gastric), and grade (low-and high-grade). The frequency of high-grade dysplasia was significantly higher in the gastric immunophenotype (68.0 %) than in the other immunophenotypes (47.1 % and 13.6 %, in hybrid and intestinal, respectively). Within cases with intestinal immunophenotype, dysplasia was graded as low in most cases (86.4 %) (p = 0.001). Gastric immunophenotype encompassed cases classified by conventional histology as gastric (72.0 %) and intestinal (28.0 %); hybrid immunophenotype encompassed cases classified by histology as gastric (35.3 %) and intestinal (64.7 %); and all cases of the intestinal immunophenotype displayed features of the adenomatous/intestinal histotype (p \ 0.0001). Table 5 shows the relationship between the presence of the coexistent intramucosal adenocarcinoma and the features of dysplasia (grade, histotype, and immunophenotype). In 20 of 64 cases (31.3 %), there was a coexistent carcinoma at the periphery of the dysplastic lesions, the latter displaying the following features: high grade (75.0 %; p = 0.001); gastric histotype (60.0 %; p = 0.024); gastric immunophenotype (65.0 %, 20.0 %, and 15.0 % for gastric, hybrid, and intestinal immunophenotypes, respectively; p = 0.013). Gastric dysplasia at the periphery of invasive carcinoma, when compared with gastric dysplasia in the absence of invasive carcinoma, displayed a significantly lower frequency of expression of synaptophysin and chromogranin (30.0 % and 40.0 %; p = 0.006 and p = 0.025, respectively).
Discussion
Gastric carcinogenesis is a complex process, requiring the elucidation of putative distinct pathways. According to the so-called Correa [4] model, gastric carcinogenesis is a multistep and multifactorial process that, in many cases, appears to involve a progression from normal mucosa, through chronic atrophic gastritis and intestinal metaplasia, to dysplasia and invasive carcinoma. However, evidence from the literature points to the possible existence of alternative pathways in which intestinal metaplasia may not be involved. Evidence stems mainly from the study of tiny early GCs arising in nonmetaplastic mucosa, as described by Japanese authors [14, 15] as well as the studies of the expression of markers of gastric differentiation in dysplasia and gastric adenocarcinoma [7, 10, 16, 17 ]. The latter demonstrate that both types of lesions may express, predominantly or exclusively, markers of gastric differentiation, raising the possibility of an origin in native gastric mucosa, rather than in intestinal metaplastic lesions. The role of spasmolytic polypeptide-expressing metaplasia (SPEM) in the pathogenesis of the lesions with gastric immunophenotype remains to be elucidated. Other evidence stems from hereditary gastric cancer models [hereditary diffuse gastric cancer and gastric adenocarcinoma and proximal polyposis of the stomach (HDGC and GAPPS)] in which GC, diffuse/poorly cohesive type, and intestinal/tubular type, respectively, originate in nonmetaplastic gastric epithelium (fundic gland polyps in the case of GAPPS) [18, 19] . Our study provides additional evidence in favor of de novo neoplastic transformation from native gastric mucosa (37.9 % of the dysplastic lesions displayed ''pure'' gastric immunophenotype).
Another relevant issue is the risk of malignant transformation of the different types of gastric dysplasia. Our results show that within the group of cases immunophenotyped as gastric, the majority were classified as highgrade dysplasia (68.0 %; p = 0.001). At variance, within cases immunophenotyped as intestinal, low-grade dysplasia was the most frequent (86.4 %; p = 0.001). These findings are in keeping with those recently reported by Nishimura et al. [14] , but differ from the results reported by Abraham et al. [20] ; the latter showed that intestinal-type adenomas were more likely than gastric-type adenomas to display high-grade dysplasia and adenocarcinoma in the polyps. A major difference from this study is that although the series studied by Abraham et al. [20] is composed of polypoid adenomas, our series is constituted by nonpolypoid dysplasia, not including polypoid/protruded lesions.
HER2 amplification was observed in three cases, immunophenotyped as gastric or hybrid. These findings show that HER2 amplification may be an early event in gastric carcinogenesis, as observed by Fassan et al. [21] .
The results herein obtained in dysplasia with gastric immunophenotype (higher frequency of high-grade lesions, expression and amplification of HER2) suggest that this type of dysplasia may be an important factor in gastric carcinogenesis.
The high frequency of cases with high proliferative index (Ki-67) in gastric and hybrid immunophenotypes (84.0 % and 94.1 %, respectively) when compared with the intestinal immunophenotype (63.6 %; p = 0.05) is in keeping with the features of aggressiveness identified in dysplastic lesions with gastric differentiation. At variance with other studies [22, 23] , we have not found a significant difference in the Ki-67 proliferation index according to the grade of dysplasia.
In this study, we observed that the expression of CDX2 is correlated with the intestinal immunophenotype (100 % of the cases), in keeping with data previously reported [9] . In accordance with Park et al. [9] , a decreased expression of CDX2 was observed in cases with gastric immunophenotype (80 % of the cases; decreased intensity of immunoreactivity). However, there is controversy in the literature regarding the expression of CDX2 in gastric dysplasia, probably reflecting the lack of subtyping of dysplasia in the different studies [9, 24, 25] .
In some cases with intestinal immunophenotype, small nests of neuroendocrine cells were observed, qualifying for neuroendocrine hyperplasia as reported in the literature [26, 27] . It is likely that adenomatous/intestinal dysplasia and neuroendocrine hyperplasia both arise in the setting of chronic atrophic gastritis, as previously suggested in neuroendocrine hyperplasia within gastric hyperplastic polyps [28] . However, further studies are needed to elucidate the biological meaning of this event.
In the present study we observed that higher expression of TP53 significantly correlated with the intestinal immunophenotype (p = 0.034) and was also more frequently observed in high-grade dysplasia, although this association was not significant (p = 0.070; data not shown). In previous studies, an increased frequency of TP53 overexpression along the progress of gastric carcinogenesis was observed. However, in these studies the immunohistochemical subtyping of gastric dysplasia was not performed [29] . Kushima et al. [30] showed that the frequency of TP53 expression was significantly higher in intestinal-type adenomas than in gastric-type adenomas, in keeping with the present study, and was higher in high-grade dysplasia than in low-grade dysplasia, leading to the suggestion that TP53 alterations occur earlier in the carcinogenetic sequence along the intestinal rather than the gastric differentiation pathway [30] . Summing up, our results point to the existence of two major types of dysplasia in the stomach. The gastric immunophenotype is significantly associated with highgrade dysplasia (p = 0.001), high proliferative index (Ki-67) (p = 0.050), and coexistence of intramucosal adenocarcinoma (p = 0.013). The intestinal immunophenotype was shown to be significantly associated with low-grade dysplasia (p = 0.001), overexpression of TP53 (p = 0.034), and neuroendocrine markers (p = 0.003 for synaptophysin and p \ 0.0001 for chromogranin).
Recently, gene expression profiling using mRNA consensus clustering has revealed three distinct gastric cancer subtypes: mesenchymal, proliferative, and metabolic [31] . The metabolic subtype is characterized by the expression of genes normally expressed in gastric mucosa, involved in metabolic processes and digestion, and the expression of trefoil peptides [31] that are coexpressed in normal mucosa of the stomach with gastric mucins. These data are in keeping with the results of our previous studies showing the expression of trefoil peptides (and gastric mucins) in a subset of dysplastic and adenocarcinomatous lesions of the stomach [7, 16, 17] , supporting the existence of a pathway of gastric carcinogenesis with gastric differentiation.
In face of the evidence we collected and that from the literature, we feel tempted to suggest that epithelial dysplasia of the stomach with gastric immunophenotype may represent the putative precursor lesion in a pathway of gastric carcinogenesis originated de novo from the native gastric mucosa, leading to a subset of glandular GCs with gastric differentiation.
